Garvey Institute news | April 30, 2022
Our Innovation Grants Program launched in 2020 funded a project led by Amy Starosta, PhD, Jeanne Hoffman, PhD, and Kari Stephens, PhD, called “Opioid prescription and use following traumatic brain injury”.
News & Stories
Inside the Seattle lecture room where experts are brainstorming the future of psychedelic research
The Seattle Times | April 23, 2022
Scientists, doctors, advocacy workers, and other community members gathered to discuss the next frontier of treating substance-use disorders and addiction: psychedelics. The meeting was convened by the Center for Novel Therapeutics in Addiction Psychiatry led by Nathan Sackett, MD and was sponsored, in part, by the Garvey Institute for Brain Health Solutions.
Novel Therapeutics in Addiction Psychiatry Symposium
Department news | April 21, 2022
A growing body of research suggests that the use of psychedelic compounds combined with behavioral interventions may provide powerful treatment options for a range of addictions including alcohol use disorder, opioid use disorder, tobacco use disorder and others.
Creating connections with the African American community to find the best ways to assess cognitive aging and mental health during a pandemic
ARDC News | March 17, 2022
Debby Tsuang, MD, MSc, and her team are researching the best remote health tools to assess mental health symptoms for African Americans and better include them in research. Written by Lori Mae Yvette Calibuso Acob, Brain Health Science Writing intern at the Garvey Institute for Brain Health Solutions.
The Garvey Institute for Brain Health Solutions hosts first Annual Meeting
Department news | January 31, 2022
The Garvey Institute for Brain Health Solutions reached a milestone by holding its first Annual Meeting.
To fight opioid crisis, UW researchers take new shot at developing vaccine against addictive drugs
The Seattle Times | January 5, 2022
Marco Pravetoni, PhD, with funding from The Garvey Institute for Brain Health Solutions, will lead UW Medicine’s new Center for Medication Development for Substance Use Disorders. He and collaborators in New York and New Jersey are running the first-ever opioid vaccine trial in humans in the U.S.
New ECHO program will support care of people with TBI
Department news | December 28, 2021
The ECHO (Extension for Community Healthcare Outcomes) model uses a virtual educational lecture series and patient case discussion to improve provider preparedness to treat patients and improve patient outcomes. Our latest ECHO launch will test whether the model can enhance the care of traumatic brain injury (TBI).
Ketamine therapy: Seattle clinic’s novel mental health treatment
KING 5 | November 17, 2021
A Mountlake Terrace clinic is using a novel therapy on some patients with treatment-resistant mental health challenges — but is it safe? Nathan Sackett, PhD, says psychedelics are only truly therapeutic when combined with professional psychotherapy.
Can magic mushrooms help ease anxiety and depression?
Right as Rain | November 15, 2021
Microdosing psilocybin has become trendy among people hoping to alleviate anxiety or increase creativity. Nathan Sackett, MD, talks about its promise as a therapeutic agent and his plans to build a novel therapeutics research program that will explore the pairing of compounds like psilocybin and ketamine with behavioral interventions to treat addictions.
DOD funds $4.3M human trial on device to enhance sleep
UW Medicine newsroom | October 26, 2021
Jeffrey Iliff, PhD, is co-PI of the first human trial of a device to speed up and enhance glymphatic function (brain cleansing) that occurs when we sleep. The trial is funded by the U.S. Department of Defense and based on research funded by the Garvey Institute for Brain Health Solutions. The story was covered in Patch, GeekWire, KXL, FOX 13, KOIN, and KIRO 7, among others.